From 67% to 97%: That’s a big improvement

Point-of-sale edit upped % of Rx with <7 days supply

February 9, 2020

A point-of-sale edit helped decrease large opioid supplies for new users, with a 30 percent increase in prescriptions of less than seven days supply

Evidence shows that a three-day opioid prescription is enough most of the time. The Centers for Disease Control (2016) provided these guidelines, and many states have passed laws that support them. These guidelines have worked their way into doctors’ prescribing habits, but for many, it’s a slow process. This study demonstrates how benefit design can have an immediate impact on prescribing behavior. This Blue Plan implemented a point-of-sale edit to limit new opioid prescriptions to less than seven days supply. This plan’s compliance rate jumped from 67 percent to 97 percent.

Short Acting Opioid Duration Edit Substantially Reduces Large Day Supply for Commercially Insured Opioid Naïve Members Compared to a Control Group without an Edit (Fall 2019)

Related research

Scientific presentations

August 1, 2021

Prime’s analytics uncovers the hidden ups and downs behind the flat drug trend for MS DMDs

Insights from integrated medical and pharmacy claims show a big upswing in one…

Scientific presentations

June 21, 2021

Break autoimmune (AI) into indication-specific info for actionable strategy

Prime uses integrated medical and pharmacy data and breaks down largest drug category…

Scientific presentations

April 21, 2021

Prime links changes in adherence rates with total cost of care

Prime’s unique study of Medicare Advantage members uses integrated benefits data to show…